Blue cone monochromacy is a rare X-linked retina disorder. It causes a complete or near-complete loss of function in the L- and M-cones responsible for color vision.

Dysfunction of cone cells in the retina has three classes: (1) rod monochromacy, in which none of the three types of cones, L (long wavelength-sensitive)-, M (middle wavelength-sensitive)- or S ...

--Adverum Biotechnologies, Inc., a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, announced the U.S. Food and Drug Administration has granted Orphan ...

ADVM-062, a novel gene therapy candidate, received orphan drug designation from the FDA for the treatment of blue cone monochromacy, according to a press release from Adverum Biotechnologies.The ...

(HealthDay)—Imagine a world in black and white. That's the plight of people with an extremely rare condition called blue cone monochromacy, an inherited eye disease that renders people unable to ...

Blue Cone Monochromacy, a rare form of colorblindness, affects 1 in 100,000 individuals. It leads to poor or no color discrimination, which is why the photo above looks sort of like it’s been ...

(2016-01-06) AGTC and BCM Families Foundation Announce Collaboration to Develop AAV-Based Gene Therapy for Blue Cone Monochromacy. Stockhouse.com uses cookies on this site. By continuing to use our ...

- ADVM-062 is designed as a potential treatment for blue cone monochromacy (X-linked incomplete achromatopsia) -REDWOOD CITY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc ...